Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in: Wiener klinische Wochenschrift 23-24/2020

20.05.2020 | review article

Recommendations for driving after implantable cardioverter defibrillator implantation and the use of a wearable cardioverter defibrillator

Different viewpoints around the world

verfasst von: Mona Cooper, M.D., Theresa Berent, M.D., Prim. Univ. Prof. Dr. Johann Auer, Prim. PD Dr. Robert Berent

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 23-24/2020

Einloggen, um Zugang zu erhalten

Summary

The use of implantable cardioverter defibrillators (ICD) has been shown to improve survival in patients at risk of sudden cardiac death; however, due to the continuous risk of sudden loss of consciousness during arrhythmia or ICD intervention, they pose a potential risk to other road users while driving. A large number of opinions and recommendations from authorities and medical societies all over the world exist regarding driving restrictions after ICD implantation. This analysis provides an overview of the recommendations on driving restrictions from several countries. Furthermore, the use of the wearable and the subcutaneous ICD are taken into account.
Vorheriger Artikel Partial oral antibiotic therapy is non-inferior to intravenous therapy in non-critically ill patients with infective endocarditis
Nächster Artikel Recommendations on the utilization of telemedicine in cardiology
Literatur
1.
Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793–867.PubMed
2.
Vijgen J, Botto G, Camm J, Hoijer CJ, Jung W, Le Heuzey JY, et al. Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators. Eur J Cardiovasc Nurs. 2010;9:3–14.PubMed
3.
Raatikainen MJP, Arnar DO, Zeppenfeld K, Merino JL, Levya F, Hindriks G, et al. Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European Heart Rhythm Association. Europace. 2015;17:i1–75.PubMed
4.
Kremers MS, Hammill SC, Berul CI, Koutras C, Curtis JS, Wang Y, et al. The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm. 2013;10(4):e59–65.PubMed
5.
-. Assessment of the cardiac patient for fitness to drive. Can J Cardiol. 1992;8:406–19.PubMed
6.
-. Assessment of the cardiac patient for fitness to drive: 1996 update. Can J Cardiol. 1996;12:1164–82.PubMed
7.
Jung W, Luderitz B. Driving and the implantable cardioverter defibrillator. Study Group on ICD and Driving. Lancet. 1996;348:687–8.PubMed
8.
Jung W, Anderson M, Camm A, Jordaens L, Petch M, Rosenqvist M. Recommendations for driving of patients with implantable cardioverter defibrillators. Study Group on ‘ICD and Driving’ of the Working Groups on Cardiac Pacing and Arrhythmias of the European Society of Cardiology. Eur Heart J. 1997;18:1210–9.PubMed
9.
Petch M. Driving and heart disease. Eur Heart J. 1998;19:1165–77.PubMed
10.
Simpson C, Ross D, Dorian P. CCS Consensus Conference 2003: Assessment of the cardiac patient for fitness to drive and fly—executive summary primary panel assessment of the cardiac patient for fitness to drive. Can J Cardiol. 2004;20(13):1313–23.
11.
Epstein AE, Baessler CA, Curtis AB, Estes NAM, Gersh BJ, Grubb B, et al. Addendum to personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scient.statem. from the Am. Heart Ass. and the North Am. Soc. of Pacing and Electrophysi. Circulation. 2007;115(9):1170–6.PubMed
12.
Epstein AE, Miles WM, Benditt DG, Camm AJ, Darling EJ, Friedman PL, et al. Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing. Circulation. 1996;94(5):1147–66.PubMed
13.
Lampert R, Joska T, Burg MM, Batsford WP, McPherson CA, Jain D. Emotional and physical precipitants of ventricular arrhythmia. Circulation. 2002;106(14):1800–5.PubMed
14.
Taggart P, Gibbons D, Somerville W. Some effects of motor-car driving on the normal and abnormal heart. Br Med J. 1969;4(5676):130–4.PubMedPubMedCentral
15.
16.
Kou WH, Calkins H, Lewis RR, Bolling SF, Kirsch MM, Langberg JJ, et al. Incidence of loss of consciousness during automatic implantable cardioverter-defibrillator shocks. Ann Intern Med. 1991;115(12):942–5.PubMed
17.
Bänsch D, Brunn J, Castrucci M, Weber M, Gietzen F, Borggrefe M, et al. Syncope in patients with an implantable cardioverter-defibrillator: incidence, prediction and implications for driving restrictions. J Am Coll Cardiol. 1998;31(3):608–15.PubMed
18.
Freedberg NA, Hill JN, Fogel RI, Prystowsky EN. Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: Implications for antiarrhythmic therapy and driving restrictions. J Am Coll Cardiol. 2001;37(7):1910–5.PubMed
19.
Trappe HJ, Wenzlaff P, Grellman G. Should patients with implantable cardioverter-defibrillators be allowed to drive? Observations in 291 patients from a single center over an 11-year period. J Interv Card Electrophysiol. 1998;2(2):193–201.PubMed
20.
Klein RC, Raitt MH, Wilkoff BL, Beckman KJ, Coromilas J, Wyse DG, et al. Analysis of implantable cardioverter defibrillator therapy in the antiarrhythmics versus implantable defibrillators (AVID) trial. J Cardiovasc Electrophysiol. 2003;14(9):940–8.PubMed
21.
Buber J, Luria D, Gurevitz O, Bar-Lev D, Eldar M, Glikson M. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population. Europace. 2014;16(2):227–34.PubMed
22.
Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7(1):164–70.PubMed
23.
Lampert R. Managing with pacemakers and Implantable cardioverter defibrillators. Circulation. 2013;128(14):1576–85.PubMed
24.
Tan VH, Ritchie D, Maxey C, Sheldon R. Prospective assessment of the risk of vasovagal syncope during driving. JACC Clin Electrophysiol. 2016;2(2):203–8.PubMed
25.
Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, Tofler GH, et al. Heart failure and the risk of shocks in patients with Implantable cardioverter defibrillators: results from triggers of ventricular arrhythmias (TOVA) study. Circulation. 2004;109(11):1386–91.PubMed
26.
Larsen GC, Stupey MR, Walance CG, Griffith KK, Cutler JE, Kron J, et al. Recurrent cardiac events in survivors of ventricular fibrillation or tachycardia. JAMA. 1994;271(17):1335.9.PubMed
27.
28.
Driver & Vehicle Licensing Agency U. Assessing fitness to drive—a guide for medical professionals. 2018. pp. 1–142.
29.
Abello M, Merino JL, Peinado R, Gnoatto M, Arias MA, Gonzalez-Vasserot M, et al. Syncope following cardioverter defibrillator implantation in patients with spontaneous syncopal monomorphic ventricular tachycardia. Eur Heart J. 2006;27(1):89–95.PubMed
30.
Curtis AB, Conti JB, Tucker KJ, Kubilis PS, Reilly RE, Woodard DA. Motor vehicle accidents in patients with an implantable cardioverter-defibrillator. J Am Coll Cardiol. 1995;26(1):180–4.PubMed
31.
Lerecouvreux M, Ait Said M, Paziaud O, Perrier E, Carlioz R, Lavergne T, et al. Automobile driving and implantable defibrillators. Arch Mal Coeur Vaiss. 2005;98:288–93.PubMed
32.
Akiyama T, Powell JL, Mitchell LB, Ehlert FA, Baessler C. Resumption of driving after life-threatening ventricular tachyarrhythmia. N Engl J Med. 2001;345(6):391–7.PubMed
33.
Albert CM, Rosenthal L, Calkins H, Steinberg JS, Ruskin JN, Wang P, et al. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias. Results from the TOVA study. J Am Coll Cardiol. 2007;50(23:2233–40.
34.
35.
36.
37.
Bleakley JF, Akiyama T. Driving and arrhythmias: implications of new data. Card Electrophysiol Rev. 2003;7(1):77–9.PubMed
38.
Thijssen J, Borleffs CJW, Van Rees JB, De Bie MK, Van Der Velde ET, Van Erven L, et al. Driving restrictions after implantable cardioverter defibrillator implantation: An evidence-based approach. Eur Heart J. 2011;32(21):2678–87.PubMedPubMedCentral
39.
Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933–40.PubMed
40.
Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med. 2002;337(22):1569–75.
41.
Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, et al. Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J Cardiovasc Electrophysiol. 2014;25(1):52–9.PubMed
42.
Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary heart disease. N Engl J Med. 1999;341(25):1882–90.PubMed
43.
Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.PubMed
44.
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.PubMed
45.
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50.PubMed
46.
Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481–8.PubMed
47.
Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, et al. Strategic programming of detection and therapy parameters in Implantable Cardioverter-defibrillators reduces shocks in primary prevention patients. Results from the PREPARE (primary prevention parameters evaluation) study. J Am Coll Cardiol. 2008;52(7):541–50.PubMed
48.
Gasparini M, Menozzi C, Proclemer A, Landolina M, Iacopino S, Carboni A, et al. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary preventi. Eur Heart J. 2009;30(22):2758–67.PubMedPubMedCentral
49.
Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367(24):2275–83.PubMed
50.
Watanabe E, Abe H, Watanabe S. Driving restrictions in patients with implantable cardioverter defibrillators and pacemakers. J Arrhythmia. 2017;33(6):594–601.
51.
Conti JB, Woodard DA, Tucker KJ, Bryant B, King LC, Curtis AB. Modification of patient driving behavior after implantation of a cardioverter defibrillator. Pacing Clin Electrophysiol. 1997;20(9):2200–4.PubMed
52.
Raviele A, Gasparini G. Italian multicenter clinical experience with endocardial defibrillation: acute and long-term results in 307 patients. Pacing Clin Electrophysiol. 1995;18(3):599–608.PubMed
53.
Epstein AE, Baker JH, Beau SL, Deering TF, Greenberg SM, Goldman DS. Performance of the St. Jude Medical Riata Leads. Heart Rhythm. 2009;6(2):204–9.PubMed
54.
Gold MR, Peters RW, Johnson JW, Shorofsky SR. Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and submuscular approaches. J Am Coll Cardiol. 1996;28(5):1278–82.PubMed
55.
Simpson C, Dorian P, Gupta A, Hamilton R, Hoffmaster B, Klein G, et al. CCS Consensus Conference 2003: assessment of the cardiac patient for fitness to drive and fly—executive summary. Can J Cardiol. 2004;20(13):1314–20.PubMed
56.
Steinbeck G, Dorwarth U, Mattke S, Hoffmann E, Markewitz A, Kaulbach H, et al. Hemodynamic deterioration during ICD implant: predictors of high-risk patients. Am Heart J. 1994;12 7:1064–7.
57.
Steinbach K, Merl O, Frohner K, Hief C, Nurnberg M, Kaltenbrunner W, et al. Hemodynamics during ventricular tachyarrhythmias. Am Heart J. 1994;127:1102–6.PubMed
58.
Dichtl W, Wolber T, Paoli U, Brüllmann S, Stühlinger M, Berger T, et al. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients. Clin Cardiol. 2011;34(7):433–6.PubMedPubMedCentral
59.
Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II. Frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51(14):1357–65.PubMed
60.
Saxon LA, Hayes DL, Gilliam FR, Heidenreich PA, Day J, Seth M, et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation. 2010;122(23):2359–67.PubMed
61.
van Rees JB, Borleffs CJW, de Bie MK, Stijnen T, van Erven L, Bax JJ, et al. Inappropriate implantable cardioverter-defibrillator shocks. J Am Coll Cardiol. 2011;57(5):556–62.PubMed
62.
Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110(25):3760–5.PubMed
63.
Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009–17.PubMedPubMedCentral
64.
Park KW, Kang SH, Kang HJ, Koo BK, Park BE, Cha KS, et al. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE noninferiority trial. J Am Coll Cardiol. 2014;63(25):2805–16.PubMed
65.
Proietti R, Labos C, Davis M, Thanassoulis G, Santangeli P, Russo V, et al. A systematic review and meta-analysis of the association between Implantable cardioverter-defibrillator shocks and long-term mortality. Can J Cardiol. 2015;31:270–7.PubMed
66.
Streitner F, Herrmann T, Kuschyk J, Lang S, Doesch C, Papavassiliu T, et al. Impact of shocks on mortality in patients with ischemic or dilated cardiomyopathy and defibrillators implanted for primary prevention. Plos One. 2013;8(5):1–7.
67.
Strickberger SA, Canby R, Cooper J, Coppess M, Doshi R, John R, et al. Association of antitachycardia pacing or shocks with survival in 69,000 patients with an implantable defibrillator. J Cardiovasc Electrophysiol. 2017;28(4):416–22.PubMed
68.
Merchant FM, Hoskins MH, Benser ME, Roberts G, Bastek AN, Knezevic A, et al. Time course of subsequent shocks after initial implantable cardioverter-defibrillator discharge and implications for driving restrictions. JAMA Cardiol. 2016;1(2):181–8.PubMed
69.
Kim MH, Zhang Y, Sakaguchi S, Goldberger JJ. Time course of appropriate implantable cardioverter-defibrillator therapy and implications for guideline-based driving restrictions. Heart Rhythm. 2015;12(8):1728–36.PubMed
70.
Fröhlig G. Komplikationen der Defibrillatortherapie Herzschrittmacher- und Defibrillator-Therapie: Indikation – Programmierung – Nachsorge. Stuttgart, New York: Thieme; 2006. pp. 407–22.
71.
Watanabe E, Okajima K, Shimane A, Ozawa T, Manaka T, Morishima I, et al. Inappropriate implantable cardioverter defibrillator shocks—incidence, effect, and implications for driver licensing. J Interv Card Electrophysiol. 2017;49(3):271–80.PubMedPubMedCentral
72.
Smith T. Driving after ventricular arrhythmias. N Engl J Med. 2001;345:451–2.PubMed
73.
Burke MC, Gold MR, Knight BP, Barr CS, Theuns DAMJ, Boersma LVA, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2‑year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol. 2015;65(16):1605–15.PubMed
74.
Olde Nordkamp LRA, Knops RE, Bardy GH, Blaauw Y, Boersma LVA, Bos JS, et al. Rationale and design of the PRAETORIAN trial: A Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J. 2012;163(5):753–60.PubMed
75.
Kusumoto FM, Bailey KR, Chaouki AS, Deshmukh AJ, Gautam S, Kim RJ et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018;138(13):e392–414.PubMed
76.
Schwab JO, Bänsch D, Israel C, Nowak B. Stellungnahme zum Einsatz des tragbaren Kardioverter/Defibrillators. Kardiologe. 2015;9(2):165–70.
77.
Scherr D, Mörtl D, Keller H, Ebner C. Positionspapier zum Einsatz des tragbaren Kardioverter-Defibrillators // Wearable cardioverter-defibrillator—a review. Austrian J Cardiol. 2017;24(9/10):206–11.
78.
Reek S, Burri H, Roberts PR, Perings C, Epstein AE, Klein HU, et al. The wearable cardioverter-defibrillator: current technology and evolving indications. Europace. 2017;19(3):335–45.PubMed
79.
Reek S, Geller JC, Meltendorf U, Wollbrueck A, Szymkiewicz SJ, Klein HU. Clinical efficacy of a wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks. Pacing Clin Electrophysiol. 2003;26(10):2016–22.PubMed
80.
Klein HU, Meltendorf U, Reek S, Smid J, Kuss S, Cygankiewicz I, et al. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD). Pacing Clin Electrophysiol. 2010;33:353–67.PubMed
81.
Feldman AM, Klein H, Tchou P, Murali S, Hall WJ, Mancini D, et al. Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of WEARIT/BIROAD. Pacing Clin Electrophysiol. 2004;27(1):4–9.PubMed
82.
Sharma PS, Bordachar P, Ellenbogen KA. Indications and use of the wearable cardiac defibrillator. Eur Heart J. 2017;38(4):258–67.PubMed
83.
Kutyifa V, Moss AJ, Klein H, Biton Y, McNitt S, MacKecknie B, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II registry). Circulation. 2015;132(17):1613–9.PubMed
84.
Epstein AE, Abraham WT, Bianco NR, Kern KB, Mirro M, Rao SV, et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. J Am Coll Cardiol. 2013;62(21):2000–7.PubMed
85.
Chung MK, Szymkiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol. 2010;56(3):194–203.PubMedPubMedCentral
86.
Ponikowski P, Voors A. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC): developed with the special contribution. Russ J Cardiol. 2017;141:7–81.
87.
Wäßnig NK, Günther M, Quick S, Pfluecke C, Rottstädt F, Szymkiewicz SJ, et al. Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circulation. 2016;134(9):635–43.PubMedPubMedCentral
88.
Odeneg T, Ebner C, Mortl D. Indications for and outcome in patients with the wearable cardioverter defibrillator (WCD)—results of the austrian WCD registry. Wien Klin Wochenschr. 2016;128:229.
89.
Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, et al. Wearable cardioverter–defibrillator after myocardial infarction. N Engl J Med. 2018;379(13):1205–15.PubMedPubMedCentral
90.
Niwano S, Sekiguchi Y, Ishii Y, Iwasaki Y, Kato R, Okamura H, et al. Clinical usefulness of wearable cardioverter defibrillator (WCD) and current understanding of its clinical indication in Japan. Circ J. 2018;82(6):1481–6.PubMed
91.
Johansson I, Strömberg A. Experiences of driving and driving restrictions in recipients with an implantable cardioverter defibrillator—the patient perspective. J Cardiovasc Nurs. 2010;25(6):E1–10.PubMed
92.
Eckert M, Jones T. How does an implantable cardioverter defibrillator (ICD) affect the lives of patients and their families? Int J Nurs Pract. 2002;8(3):152–7.PubMed
93.
Timmermans I, Jongejan N, Meine M, Doevendans P, Tuinenburg A, Versteeg H. Decreased quality of life due to driving restrictions after cardioverter defibrillator implantation. J Cardiovasc Nurs. 2018;33(5):474–80.PubMed
94.
Hickey K, Curtis AB, Lancaster S, Larsen G, Warwick D, McAnulty J, et al. Baseline factors predicting early resumption of driving after life-threatening arrhythmias in the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. Am Heart J. 2001;142(1):99–104.PubMed
95.
Mylotte D, Sheahan RG, Nolan PG, Neylon MA, McArdle B, Constant O, et al. The implantable defibrillator and return to operation of vehicles study. Europace. 2013;15(2):212–8.PubMed
96.
Bjerre J, Rosenkranz SH, Christensen AM, Schou M, Jøns C, Gislason G, et al. Driving following defibrillator implantation: development and pilot results from a nationwide questionnaire. BMC Cardiovasc Disord. 2018;18(1):212.PubMedPubMedCentral
97.
Dicarlo LA, Winston SA, Honoway S, Reed P. Driving restrictions advised by midwestern cardiologists implanting cardioverter defibrillators: present practices, criteria utilized, and compatibility with existing state laws. Pacing Clin Electrophysiol. 1992;15:1131–6.PubMed
98.
Jongejan N, Timmermans I, Elders J, Meijer K, Meine M, Doevendans PA, et al. Driving restrictions for Dutch patients with an implantable cardioverter defibrillator compliance and associated factors. Neth Heart J. 2018;26(2):69–75.PubMed
99.
100.
Mârgulescu AD, Anderson MH. A review of driving restrictions in patients at risk of syncope and cardiac arrhythmias associated with sudden incapacity: differing global approaches to regulation and risk. Arrhythmia Electrophysiol Rev. 2019;8(2):90–98.
101.
Van Erven L, Schalij MJ. Troubleshooting implantable cardioverter-defibrillator related problems. Heart. 2008;94(5):649–60.PubMed
102.
Wilkoff BL, Fauchier L, Stiles MK, Aguinaga L, Morillo CA, Al-khatib SM, et al. Corrigendum to: 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing (Europace (2016) 2 (159–183)). Europace. 2017;19(4):580.
103.
Abboud J, Ehrlich J. Antiarrhythmic drug therapy to avoid Implantable cardioverter defibrillator shocks. Arrhythmia Electrophysiol Rev. 2016;5(2):117.
104.
105.
106.
Burger AL, Stojkovic S, Schmidinger H, Ristl R, Pezawas T. Defensive implantable cardioverter-defibrillator programming is safe and reduces inappropriate therapy—comparison of 3 programming strategies in 1,471 patients. Circ J. 2018;82(12):2976–82.PubMed
Metadaten
Titel
Recommendations for driving after implantable cardioverter defibrillator implantation and the use of a wearable cardioverter defibrillator
Different viewpoints around the world
verfasst von
Mona Cooper, M.D.
Theresa Berent, M.D.
Prim. Univ. Prof. Dr. Johann Auer
Prim. PD Dr. Robert Berent
Publikationsdatum
20.05.2020
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 23-24/2020
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01675-0

Weitere Artikel der Ausgabe 23-24/2020

Wiener klinische Wochenschrift 23-24/2020 Zur Ausgabe

consensus report

Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement

original article

Toxoplasma infection in patients with myocardial infarction

original article

A little is better than none: the biggest gain of physical activity in patients with ischemic heart disease

MUW researcher of the month

MUW researcher of the month

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungstipps:

original article

Impella in cardiogenic shock following acute myocardial infarction: a systematic review and meta-analysis